Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIIGDMC4Z)
  Drug Name Mecamylamine Drug Info Amifostine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Cytoprotective Agent
  Structure

 Mechanism of Mecamylamine-Amifostine Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Mecamylamine Amifostine
      Mechanism 1 Hypotensive effects
Neuronal acetylcholine receptor  Antagonist 		Antihypertensive agent
      Key Mechanism Factor 1
Factor Name Neuronal acetylcholine receptor Structure Sequence
Protein Family Ligand-gated ion channel (TC 1.A.9) family
Protein Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Mecamylamine and Amifostine 
      Mechanism 2 Hypotensive effects
Neuronal acetylcholine receptor  Antagonist 		Hypotensive effects
      Key Mechanism Factor 2
Factor Name Neuronal acetylcholine receptor Structure Sequence
Protein Family Ligand-gated ion channel (TC 1.A.9) family
Protein Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Mecamylamine and Amifostine 

Recommended Action
      Management If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.

References
1 Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
2 Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON.
3 Product Information. Ethyol (amifostine). Alza, Palo Alto, CA.